AstraZeneca Plc AZN and Amgen Inc.'s AMGN Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the WAYPOINT Phase 3 trial.AZN shares are trending higher. Check the fundamentals here.In the WAYPOINT trial, Tezspire demonstrated a statistically significant and clinical ...